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Background:  Atrioventricular  (AV)  block  is  one  of the  main  clinical  manifestations  in  patients  with  cardiac
sarcoidosis  (CS).  Although  steroid  therapy  is considered  to be  effective  for  AV  block,  the  efﬁcacy  has  not
been  demonstrated  in detail.
Methods and  results:  Fifteen  CS  patients  presenting  with  advanced  or complete  AV  block  were  retrospec-
tively  investigated.  All  patients  were treated  with  30 mg/day  of  prednisone  after device  implantation,
which  was  tapered  to a  maintenance  dosage  of 5–10 mg/day.  During  a  mean  follow-up  of  7.1  years,
AV  block  resolved  to  normal  conduction  or ﬁrst-degree  AV  block  in  7 patients  (recovery  group).  The
improvement  was  driven  within  the ﬁrst  week  of steroid  therapy  in  4 patients,  while  3 patients  showed
late  recovery  of AV conduction.  The  remaining  8 patients  were  classiﬁed  as  the non-recovery  group.
The  recovery  group  showed  a higher  left  ventricular  ejection  fraction  (69.4  ± 8.9%  versus  44.1  ±  19.3%,
p  =  0.029)  and  higher  prevalence  of  advanced  AV  block  (87.5%  versus  28.6%,  p =  0.040)  compared  with
those  of the non-recovery  group.  In patients  with the  recovery  group,  there  was  no  late recurrence  of AV
block  during  the  follow-up  period.
Conclusions: Early  initiation  of steroid  therapy  may  be  effective  for AV  block,  and  steroid  therapy  before
device  implantation  is  a possible  therapeutic  strategy  for some  selected  patients.
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Sarcoidosis is a common multisystem granulomatous disease of
nknown etiology [1]. Cardiac sarcoidosis (CS) is relatively rare but
ometimes life-threatening because of fatal arrhythmias or severe
ongestive heart failure. Atrioventricular (AV) block is one of the
ommon manifestations of CS which could result in syncope, and
ossibly sudden cardiac death. Currently, pacemaker implantation
s recommended for patients with advanced or complete AV block.
lthough steroid therapy is reported to be effective for AV block
2,3], the efﬁcacy has not been demonstrated in detail. This study
as performed to determine the prevalence and clinical implica-
ions for recovery of advanced AV block following steroid therapy.
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Methods
This study was retrospective with 15 CS patients (2 men  and 13
women; mean age 59.9 ± 9.7 years) presenting with advanced or
complete AV block on electrocardiography (ECG). All patients were
referred to Nippon Medical School Main Hospital or Nippon Medical
School Chiba Hokusoh Hospital for treatment of AV block between
June 1, 1995 and December 31, 2012. We  applied the guidelines for
the diagnosis of CS based on the report from the Japanese Society
of Sarcoidosis and Other Granulomatous Disorders (Table 1) [4,5].
Signiﬁcant coronary artery disease was excluded by angiography
in all patients. Patients with known other cardiac diseases were
also excluded from the present investigation. All of the patients
were treated with steroid after device implantation, and the initial
dosage was 30 mg/day of prednisone or its equivalent on alternate
days, which was tapered over a period of 6 months to a maintenance
dosage of 5–10 mg/day. Cardiac echocardiography, gallium-67
scintigraphy, serum angiotensin-converting enzyme (ACE) and
plasma B-type natriuretic peptide (BNP) concentrations, electro-
physiological study, cardiovascular magnetic resonance imaging
vier Ltd. All rights reserved.
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Table  1
Clinical diagnosis group: extracardiac sarcoidosis is diagnosed histologically or clin-
ically and satisﬁes the following conditions (more than 2 of 4 major criteria, or 1 in
4 major criteria and more than 2 in 5 minor criteria are satisﬁed) and more than 1
in 6 basic diagnostic criteria.
Major criteria
(a)  Advanced AV block
(b)  Basal thinning of the interventricular septum
(c) Positive cardiac 67Ga uptake
(d) Depressed ejection fraction of the left ventricle (LVEF < 50%)
Minor criteria
(a)  Abnormal ECG ﬁndings: ventricular arrhythmias (VT, multifocal or frequent
PVCs), CRBBB, axis deviation, or abnormal Q-wave
(b)  Abnormal echocardiography: regional abnormal wall motion or
morphological abnormality (ventricular aneurysm, wall thickening)
(c)  Nuclear medicine: perfusion defect detected by 201Tl myocardial
scintigraphy  or 99Tc myocardial scintigraphy
(d) Gd-enhanced MRI: delayed enhancement of myocardium
(f)  Endomyocardial biopsy: interstitial ﬁbrosis or monocyte inﬁltration over
moderate grade
AV, atrioventricular; LVEF, left ventricular ejection fraction; ECG, electrocardiogram;
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aRI,  magnetic resonance imaging; PVC, premature ventricular contraction; cRBBB,
omplete right bundle branch block; VT, ventricular tachycardia.
CMR), and endomyocardial biopsy were assessed before steroid
herapy. Left ventricular (LV) end-diastolic and end-systolic dimen-
ions were determined from cardiac echocardiography and LV
jection fraction (EF) was measured by the Modiﬁed Simpson’s
ethod. Serum ACE concentrations were measured by a colori-
etric method (colorimetric assay kit; Fujirebio, Tokyo, Japan)
ith p-hydroxyhippuryl-l-histidyl-l-leucine as the substrate [6]
nd plasma BNP concentrations were determined with a speciﬁc
mmunoradiometric assay for human BNP with commercial kits
able 2
linical characteristics of the study patients.
Patient no. Age Sex Type of AV
block
LVEF  (%) IVST
(mm)
BNP
(pg/ml)
ACE
(U/L)
1 56 F Advanced 78 12 141.0 10.6 
2 63 F Advanced 68 8 21.7 30.0 
3 43 F Complete 80 6 78.1 19.9 
4  61 F Advanced 53 9 124.0 19.4 
5  65 F Advanced 72 9 48.9 9.7 
6 58 F Advanced 66 9 212.8 32.0 
7 65 F Complete 69 7 54.3 25.6 
8  63 F Complete 56 7 643.0 20.2 
9  54 F Complete 72 5 149.8 13.2 
10  60 F Complete 19 6 244.4 14.8 
11  73 F Advanced 34 5 834.8 10.9 
12 73 F Complete 32 6 75.6 16.2 
13  46 M Complete 40 10 162.0 11.5 
14  57 M Complete 69 10 74.1 31.4 
15  55 F Complete 31 9 208.2 21.0 
V, atrioventricular; LVEF, left ventricular ejection fraction; ACE, angiotensin convertin
mplantable cardioverter deﬁbrillator; IVST, intraventricular septal thickness.
able 3
omparison of parameters between recovery group and non-recovery group.
Recovery group (n = 7) 
Age (years) 58.7 ± 7.7
Male  0 
BNP  (pg/ml) 97.2 ± 66.1 
LVEF  (%) 69.4 ± 8.9 
IVST  (mm) 8.6 ± 1.9 
ACE  (U/ml) 21.0 ± 8.8 
Ga  uptake (heart) 3 
Type  of AVB (advanced/complete) 5/2 
ata are presented as mean ± SD or no. of patients. BNP, B-type natriuretic peptide; LV
ngiotensin-converting enzyme; Ga, gallidium; AVB, atrioventricular block.diology 62 (2013) 320–325 321
(Shionoria kit; Shionogi and Kyowa Medex, Tokyo, Japan). The study
protocol was approved by the ethical committee of Nippon Med-
ical School, and written informed consent was  obtained from all
patients.
Statistical analysis
Measurements are presented as mean value ± SD.  Compar-
isons of measurements between two  groups were analyzed by
Mann–Whitney U-test. Fisher exact test was used for discrete vari-
ables. A p-value < 0.05 was considered statistically signiﬁcant.
Results
During a mean follow-up of 7.1 ± 5.3 years, AV block resolved to
normal conduction or ﬁrst-degree AV block in 7 patients (recov-
ery group). The improvement was  driven within the ﬁrst week
of steroid therapy in 4 patients, while 3 patients showed late
recovery of AV conduction (3 weeks, 6 months, and 14 months,
respectively). The remaining 8 patients were classiﬁed as the non-
recovery group. Clinical characteristics of the study patients are
shown in Table 2. The recovery group showed a higher LVEF
(69.4 ± 8.9% versus 44.1 ± 19.3%, p = 0.029) and higher prevalence of
advanced AV block (87.5% versus 28.6%, p = 0.040) compared with
those of the non-recovery group (Table 3). However, there no were
no signiﬁcant differences in the other parameters. All patients wereimplantation (no. 11). In patients with the recovery group, there
was no subsequent recurrence of AV block during the follow-up
period.
Ga
uptake
(heart)
Time  to
recovery of AV
block
Other  organ
involvement
Device
(+) 3 days Lung, skin PM
Early  recovery
(+) 7 days Lung PM
}
(+) 6 days Lung PM
(−) 1 day Eye, lung ICD
(−) 3 weeks Skin PM
Late  recovery(−) 6 months Lung PM
}
(−) 14 months Lung PM
(−) – Lung, PM
Non-recovery
(−) – Lung PM
(−) – Lung ICD
(−) – Lung PM
⎫⎪⎪⎪⎪⎪⎬
⎪⎪⎪⎪⎪⎭
(−) – Skin PM
(−) – Lung, ICD
(−) – Eye, lung, skin PM
(−) – Skin PM
g enzyme; BNP, B-type natriuretic peptide; Ga, Gallium-67; PM,  pacemaker; ICD,
Non-recovery group (n = 8) p Value
60.1 ± 9.4 0.867
2 0.475
299.0 ± 282.4 0.054
44.1 ± 19.3 0.029
7.3 ± 2.1 0.298
17.4 ± 6.8 0.694
1 0.282
1/7 0.041
EF, left ventricular ejection fraction; IVST, intraventricular septal thickness; ACE,
3  of Car
E
d
r
t
b
e
c
(
C
d
p
e
t
e
E
i
i
t
F
b
e
F
2
e22 K. Yodogawa et al. / Journal
lectrophysiological study
Seven patients underwent electrophysiological study. Intracar-
iac electrogram showed atrio-hisian block in two patients in the
ecovery group (Fig. 1), while infra-hisian block was detected in
hree patients in the non-recovery group. His potential could not
e recorded in two patients. Three patients performed programmed
lectrical ventricular stimulation, and sustained ventricular tachy-
ardia or ventricular ﬁbrillation was induced in one patient
no. 4).
MR
Seven patients underwent CMR. Delayed-enhancement was
etected in three patients in the recovery group (Fig. 2), and two
atients in the non-recovery group. Meanwhile, one patient in
ach group did not show delayed-enhancement. As expected, all of
he three patients with positive ﬁndings on CMR  showed delayed
nhancement in the intraventricular septum.
ndomyocardial biopsyFive  patients underwent endomyocardial biopsy. One patient
n the recovery group had pathologic active inﬂammatory ﬁnd-
ngs (non-caseating epithelioid cell granuloma, Fig. 3). However,
he remaining four patients had no speciﬁc ﬁndings.
ig. 1. Electrocardiogram (ECG) recordings before and after steroid therapy in a patient in t
lock, which recovered to normal after steroid therapy. Intracardiac electrograms show atri
lectrogram.
ig. 2. Electrocardiogram (ECG) recordings before and after corticosteroid therapy in a
:1 atrioventricular (AV) block and transient complete AV block. After steroid therapy,
nhancement (arrows) in both the inferolateral and septal walls, typical of cardiac sarcoidiology 62 (2013) 320–325
Discussion
Major ﬁndings
The  major ﬁndings of this study are as follows. (1) Steroid ther-
apy was effective for AV block in 7 of 15 patients. (2) The recovery
group showed a higher LVEF and higher prevalence of advanced
AV block compared with those of the non-recovery group. (3) The
improvement was driven within the ﬁrst week of steroid therapy in
4 patients, while 3 patients showed late recovery of AV conduction.
Efﬁcacy of steroid therapy for advanced or complete AV block in CS
In general, one should start steroid therapy after deﬁnite diag-
noses of CS. Long-term beneﬁt of steroid therapy in reducing
clinical morbidity and mortality has been demonstrated [7]. As
far as arrhythmias are concerned, Kato et al. reported that AV
block resolved in 4 of the 7 CS patients by steroid therapy, but
did not resolve or improve in any of the patients without steroid
therapy [2]. Banba et al. evaluated the effect of steroids in CS
patients presenting with ventricular tachycardia or complete AV
block. In their cohort, AV conduction improved in 5 of 9 com-
plete AV block patients after steroid therapy, while ventricular
arrhythmias were not improved after steroid therapy [3]. The
present investigation showed that steroid therapy was  effective
for AV block in 7 of 15 patients. This ratio is similar to previous
reports [2,3].
he recovery group (case no. 1). On admission, ECG showed advanced atrioventricular
o-hisian block. RAd, right atriumdistal; Rap, right atrium proxymal; HBE, His-bundle
 patient in the recovery group (case no. 4). On admission, baseline ECG showed
 AV conduction recovered to normal. Cardiac magnetic resonance shows delayed
dosis.
K. Yodogawa et al. / Journal of Cardiology 62 (2013) 320–325 323
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Aig. 3. Electrocardiogram (ECG) recordings before and after steroid therapy in a pa
lock,  which recovered to 1st degree AV block 3 weeks after steroid therapy. Endom
rom  the left ventricular endocardium (hematoxylin and eosin, 200× original magn
linical characteristics of the recovery patients
Although sporadic case reports have also shown that steroid
herapy is effective for AV block in CS [8–11], it remains unclear
hat type of patients show a good response to steroid therapy.
n the present study, the recovery group showed a higher preva-
ence of advanced AV block compared with the non-recovery group.
his result highlights the importance of early steroid therapy
efore progression to complete AV block. In addition, the recov-
ry group showed a signiﬁcantly higher LVEF compared with the
on-recovery group. From a similar point of view, steroid therapy
as reported to prevent LV remodeling and improve LV func-
ion in patients with mildly reduced LV function but not with
VEF < 30% [12]. Furthermore, our previous work has shown that
teroid therapy is effective for ventricular arrhythmias in the less
dvanced LV dysfunction (LVEF ≥ 35%) patients, but less effective in
he advanced LV dysfunction patients [13]. Therefore, early initia-
ion of steroid therapy is crucial for CS patients. Basal thinning of the
ntraventricular septum has been considered to be characteristic of
S [14]. In the present study, there were no signiﬁcant differences
n intraventricular septal thickness (IVST) between the recovery
roup and the non-recovery group. In addition, IVST remained
nchanged after steroid therapy. This may  be due to the low sen-
itivity of echocardiographic ﬁndings in detecting CS [15]. Uemura
t al. found that basal thinning of intraventricular septum is not
o common (20%), and there were no relationships between basal
hinning of intraventricular septum and AV block in CS [16].
BNP  is a hormone released mainly from the cardiac ventricles
n response to myocardial wall stress, and associated with LV dys-
unction in various cardiac conditions. As expected, serum plasma
NP concentrations were higher in the non-recovery group than
hose in the recovery group, but this did not reach statistical signif-
cance (299.0 ± 282.4 pg/ml versus 97.2 ± 66.1 pg/ml, p = 0.054). In
he present investigation, three patients showed no recovery of AV
onduction despite preserved LVEF (≥55%). The response to steroid
herapy in patients with preserved LVEF may  depend on the degree
f irreversible ﬁbrosis in the electrical conduction system. Electro-
hysiological study demonstrated atrio-hisian block in 2 patients
n the recovery group, while infra-hisian block was  detected in
 patients in the non-recovery group. Although few reports have
valuated electrophysiological properties in CS complicated with
V block, it is speculated that atrio-hisian block is observed in
he inﬂammation stage, and infra-hisian block in the ﬁbrotic stage
f the cardiac conduction system. Umetani et al. described a case
f recovery from complete AV block following steroid therapy in
hich electrophysiological study showed atrio-hisian block [8].
ccumulation of gallium-67 is often taken as a marker of diseasein the recovery group (case no. 5). Baseline ECG showed 2:1 atrioventricular (AV)
ial biopsy shows non-caseating, multinucleated granuloma on histologic specimen
on).
activity  in CS, and is reported to be useful for predicting the effect
of corticosteroid therapy [17]. However, the present study demon-
strated that gallium-67 uptake was not detected in 4 of 7 recovery
patients. This may  be due to low sensitivity of gallium-67 scintigra-
phy for detecting CS. Tadamura et al. noted that gallium-67 uptake
of the heart was  detected in only 2 of 10 CS patients, whereas all of
the patients had delayed enhancement CMR  [18]. Not surprisingly,
the gallium-67 accumulation was  diminished after steroid therapy
in 3/3 patients in the recovery group.
Serum ACE levels are sometimes elevated in CS, and consid-
ered to reﬂect disease activity. However, the present investigation
demonstrated that there were no signiﬁcant differences in ACE lev-
els between the recovery group and the non-recovery group. This
is assumed to be due to its low sensitivity for detecting disease
activity in CS or our small sample size. The sensitivity of elevated
serum ACE levels for identifying CS is reported to be as low as 37.5%
[19]. Delayed enhancement CMR  using gadolinium contrast is an
excellent technique that allows detection of minute myocardial
damage. Previous studies have demonstrated that CMR  is useful
for detecting myocardial involvement in patients with sarcoidosis
[20–22]. Smedema et al. reported that the sensitivity and speci-
ﬁcity of CMR  for identifying CS were 100% and 78%, respectively
[22]. Furthermore, Shafee et al. found that delayed enhancement
on CMR  predicts ventricular arrhythmias and poor outcome in CS
[23]. However, so far, accurate evaluation of disease activity in CS
by CMR  is difﬁcult to make. Although statistical evaluation could
not be performed because of the small number of patients, our data
showed no differences in the prevalence of delayed-enhancement
CMR between the recovery group and the non-recovery group.
Noncaseating epithelioid cell granuloma found on endomyocardial
biopsy allows a deﬁnitive diagnosis of CS. However, its sensitivity
has been reported to be low because of the patchy distribution of
lesion area [24]. In fact, we found only 1 patient with noncaseating
epithelioid cell granuloma in the present study.
Clinical implication of early recovery of AV conduction
In general, corticosteroid therapy is initiated after pacemaker
implantation because it may  lead to increased susceptibility to
infection. Some case reports have shown early recovery (≤1 week)
of AV conduction following steroid therapy [8,10]. In the present
study, 4 of 7 recovery patients showed early response to steroid
therapy, and no recurrence of AV block during the follow-up period.
Sugishita et al. reported successful steroid therapy without perma-
nent pacemaker in a patient with complete AV block due to CS
[9]. In addition, Miyazaki et al. demonstrated efﬁcacious steroid
therapy before pacemaker implantation in CS complicated with AV
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lock [10]. Our ﬁndings suggest that steroid therapy before device
mplantation is a possible therapeutic strategy for some selected
atients. In clinical settings, the strategy may  be allowed in patients
ith preserved EF and a stable escape rhythm. Even after recov-
ry of AV block, close follow-up should be taken when patients
re followed without pacemaker because there is potential risk of
ecurrence of AV block.
linical  implication of late recovery of AV conduction
In the present study, 3 patients showed late recovery (>1 week)
f AV conduction. Little is known about late recovery of AV con-
uction following steroid therapy, and the mechanism remains
nclear. Although these patients are candidates for pacemaker
mplantation, recent studies have emphasized the importance of
ot only normalization of AV synchrony but of avoiding unnec-
ssary ventricular pacing. Conventional right ventricular pacing
s associated with reduced LV function, and has been shown to
ncrease the risk of mortality and hospital admissions due to heart
ailure [25,26]. Ventricular pacing should be minimized in patients
ith recovered AV conduction since native ventricular activation
atterns are superior to those induced by ventricular pacing. There-
ore close follow up on the status of AV conduction is required, and
eprogramming of pacemaker should be considered after recovery
f AV conduction to avoid unnecessary ventricular pacing.
arly  detection of cardiac abnormality in sarcoidosis
As mentioned previously, the early detection of CS is critical for
uccessful treatment and improved prognosis. Up to the present,
MR and positron emission tomography (PET) scan have renewed
he awareness of CS [17–19,27,28]. However, the early detection
f CS remains difﬁcult because no speciﬁc tests are available. Espe-
ially, diagnosing isolated CS is still challenging because of the poor
ensitivity of endomyocardial biopsy. Akashi et al. reported that
ore than half of CS patients were initially diagnosed after heart
ransplantation by tissue analysis of the explanted heart [29]. Cur-
ently, no single test has proven consistently reliable in detecting
S. A combination of multiple testing methodologies is considered
o be the most reliable approach for the early identiﬁcation. We
reviously reported the possibility of early detection of CS using
ignal averaged ECG [30]. Reﬁnements in noninvasive studies may
elp in the early detection and management of CS.
tudy limitations
There are several limitations to this study. First, our sample size
as small, which can obscure the results of the present study. The
econd limitation is the retrospective nature of this study. In addi-
ion, the lack of a control group poses a third limitation to our study
s spontaneous recovery may  have contributed in part to our obser-
ations. A large, multicenter, controlled, randomized trial is needed
o assess the true efﬁcacy of steroid administration. The fourth lim-
tation is that the study patients are from Japan, and there may
e geographical differences in sarcoidosis that limit the broader
pplicability of the ﬁndings.
onclusions
Our  ﬁndings suggest that early initiation of steroid therapy may
e effective for AV block, and steroid therapy before device implan-
ation is a possible therapeutic strategy for some selected patients.
ven without early recovery, it is mandatory to pay attention to the
hange of ECG because certain patients show late recovery of AV
onduction during the maintenance period.
[diology 62 (2013) 320–325
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